Sun Pharmaceutical Industries share price
You have to be logged in to add this to Watchlist.- ₹1,757.70(-0.47%)March 26, 2025 15:51:18 PM IST
- NSE
- BSE
- Vol : 1.90M (NSE + BSE)Last 20 day avg : 2.23 M
Sun Pharmaceutical Industries is trading -0.47% lower at Rs 1,757.70 as compared to its last closing price. Sun Pharmaceutical Industries has been trading in the price range of 1,770.60 & 1,745.80. Sun Pharmaceutical Industries has given -6.45% in this year & 0.97% in the last 5 days. Sun Pharmaceutical Industries has TTM P/E ratio 39.53 as compared to the sector P/E of 29.60.There are 31 analysts who have initiated coverage on Sun Pharmaceutical Industries. There are 13 analysts who have given it a strong buy rating & 12 analysts have given it a buy rating. 2 analysts have given the stock a sell rating.The company posted a net profit of 2,903.38 Crores in its last quarter.Listed peers of Sun Pharmaceutical Industries include Sun Pharmaceutical Industries (-0.47%), Divis Laboratories (-0.02%), Cipla (-2.32%).The Mutual Fund holding in Sun Pharmaceutical Industries was at 12.24% in 31 Dec 2024. The MF holding has increased from the last quarter. The FII holding in Sun Pharmaceutical Industries was at 18.04% in 31 Dec 2024. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Updated on Mar 26, 2025, 07:10 PM UTC
- Dividend YieldLower than industry0.88Annual dividends as a percentage of the stock price.
- P/BHigher than historical values6.65The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values36.98Price-to-earnings ratio based on trailing 12-month earnings
- BetaMedium volatility1.00Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.05The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable- The company's revenue grew in December quarter by 10.46% from Rs 13675.46 crore to Rs 12380.70 crore, year-on-year
- The company has grown its December quarter profit by 15.04% from Rs 2523.75 crore to Rs 2903.38 crore, year-on-year
The debt to equity of the company is higher than the industry median- Company can comfortably pay off its interest obligations with its earnings
- R1
- 1,756.50
- R2
- 1,919.10
- R3
- 2,019.85
- S1
- 1,493.15
- S2
- 1,392.40
- S3
- 1,229.80
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | Bullish | 1,757.70 | -0.47 | 4,21,720.81 | 42.76 | 6.73 | 0.87 | 0.48 |
| Divis Laboratories | Bullish | 5,839.20 | -0.02 | 1,55,012.41 | 97.89 | 11.56 | 0.51 | 0.01 |
| Cipla | Bearish | 1,476.20 | -2.32 | 1,19,219.98 | 28.35 | 4.61 | 0.85 | 0.84 |
| Torrent Pharmaceuticals | Bullish | 3,230.95 | -0.04 | 1,09,345.12 | 69.06 | 16.15 | 0.98 | 24.33 |
| Dr Reddys Laboratories | Neutral | 1,163.85 | -1.41 | 97,112.24 | 18.31 | 3.57 | 0.66 | 2.12 |
- Pledged found - Promoter(s) have pledged 0.69% of shares.
- Promoter(s) have decreased pledged shares to 0.79% from 0.69% earlier.
- Promoter(s) holds a high stake in the company at 54.48%
- FIIs are invested in this company
- FIIs holding has increased by 0.03 percentage points from previous quarter
- Mutual Funds holding has increased by 0.13 percentage points from previous quarter
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-01-31 | Quarterly Results & Interim Dividend |
| 2024-10-28 | Quarterly Results |
| 2024-08-01 | Quarterly Results |
| 2024-05-22 | Audited Results & Final Dividend |
| 2024-01-31 | Quarterly Results & Interim Dividend |
- IndustryBiotechnology & Drugs
- ISININE044A01036
- BSE Code524715
- NSE CodeSUNPHARMA
Sun Pharmaceutical Industries is trading at 1757.70 as on Wed Mar 26 2025 10:21:18. This is -0.47% lower as compared to its previous closing price of 1766.00.
The market capitalization of Sun Pharmaceutical Industries is 421720.81 Cr as on Wed Mar 26 2025 10:21:18.
The average broker rating on Sun Pharmaceutical Industries is Buy. The breakup of analyst rating is given below -
- 13 analysts have given a strong buy rating
- 12 analysts have given a buy rating
- 4 analysts have given a hold rating
- 2 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Sun Pharmaceutical Industries is 1960.20 whereas the 52 wk low is 1376.75
Sun Pharmaceutical Industries can be analyzed on the following key metrics -
- TTM P/E: 39.53
- Sector P/E: 29.60
- Dividend Yield: 0.88%
- D/E ratio: -
Sun Pharmaceutical Industries reported a net profit of 9576.38 Cr in 2024.
The Mutual Fund Shareholding was 12.24% at the end of 31 Dec 2024.